Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gastrointestinal tumours, colorectal 1

2100 - NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)

Date

20 Oct 2018

Session

Poster Discussion session - Gastrointestinal tumours, colorectal 1

Presenters

Stine Winther

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

S.B. Winther1, H. Skuladottir2, E. Hofsli3, C. Shah4, M.K. Yilmaz5, P.J. Österlund6, Å. Berglund7, B. Glimelius7, C. Qvortrup8, H. Sorbye9, P. Pfeiffer10

Author affiliations

  • 1 Department Of Oncology, Department Of Clinical research, Sdu, Odense University Hospital, 5000 - Odense C/DK
  • 2 Department Of Oncology, Regional Hospital West Jutland, 7400 - Herning/DK
  • 3 Department Of Oncology, Trondheim University Hospital, Trondheim/NO
  • 4 Theme Cancer, Karolinska University Hospital, Stockholm/SE
  • 5 Department Of Oncology, Aalborg University Hospital, Aalborg/DK
  • 6 Dept. Of Oncology, Tampere University Hospital (Tays), 33521 - Tampere/FI
  • 7 Department Of Immunology, Genetics And Pathology, Uppsala University Hospital, Uppsala/SE
  • 8 Department Of Oncology, Odense University Hospital, Odense/DK
  • 9 Oncology, Haukeland Universitetssykehus, 5021 - Bergen/NO
  • 10 Academy Of Geriatric Cancer Research, Agecare, Department Of Oncology, Odense University Hospital, 5000 - Odense C/DK
More

Resources

Abstract 2100

Background

Most patients (pts) with mCRC are older than 70 years, but they are underrepresented in clinical trials. NORDIC9 evaluated efficacy of palliative treatment strategies based on S-1, which has previously demonstrated less toxicity but similar efficacy as 5FU, and here we present initial results.

Methods

Older mCRC pts (≥70 years) who were not candidates for full-dose combination therapy, were randomized to full-dose monotherapy (Arm A: S-1 30 mg/m2 po bid d 1-14 q3w, followed by irinotecan upon progression) or reduced (80%) combination therapy (Arm B: S-1 20 mg/m2 po bid d 1-14 + oxaliplatin 100 mg/m2 iv d 1 q3w, followed by S-1 + irinotecan q3w). Addition of bevacizumab (7.5 mg/kg iv d 1) before randomization was optional. Geriatric screening tools (G-8, VES-13, handgrip strength, Timed-Up-and-Go), Charlson Comorbidity Index and quality of life were evaluated at baseline. Blood samples and tumor tissue were prospectively collected. Primary endpoint was PFS. Secondary endpoints were response rate, survival and correlations between screening tools, efficacy and safety.

Results

From March 2015 to October 2017, 156 eligible/160 planned pts were randomized. Median age was 78 years (range 70-88), 51% were male, 34%/47%/19% had performance status 0/1/2. 28% received bevacizumab. Baseline characteristics were well balanced. At cut-off date (March 1st 2018) 15% continued first-line treatment and 40% were alive. There was no significant difference in RR (34% vs 40%), but PFS (5.3 vs 6.7 months, p = 0.05) and OS (11.5 vs 18.3 months, p = 0.08) were longer in arm B. Patients selected for bevacizumab had longer PFS (5.2 vs 8.5 months, p = 0.02) and OS (13.4 vs 21.4 months, p = 0.13). Treatment was tolerable, but grade 3-4 diarrhea (11% vs 3%, p = 0.04) and fatigue (10% vs 5%, p = 0.29) were more frequent in arm A and grade 3-4 neuropathy (7%) was only seen in arm B. One pt in arm B stopped therapy due to cardiac ischemia. Febrile neutropenia grade 3 was observed in 1 pt in arm B. No hand-foot-syndrome was seen.

Conclusions

Dose-reduced combination therapy with S-1 and oxaliplatin is well-tolerated in older and frail pts and may be more effective than full-dose monotherapy.

Clinical trial identification

EudraCT: 2014-000394-39.

Legal entity responsible for the study

Per Pfeiffer.

Funding

Taiho, Nordic Drugs.

Editorial Acknowledgement

Disclosure

S.B. Winther: Research support: Taiho, Nordic Drugs. C-H. Shah: Travel grants, consultancy honorarium: Nordic Group BV, Roche AG. H. Sorbye: Consultant (advisory board): Novartis, Pfizer, Keocyt; Honoraria: Novartis, Roche, Amgen, Ipsen, Merck, Nordic Drugs, Shire, Celgene; Research funding grant: Novartis, Amgen, Ipsen. P. Pfeiffer: Grants, research supports: Roche, Taiho, PledPharma, Nordic, Drugs, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings